TNFAIP3 Gene Expression in Ankylosing Spondylitis and Psoriatic Arthritis Patients and Its Relation to Disease Activity

Brief summary (registry, in English)

1. Identify gene expression of TNFAIP3 in ankylosing spondylitis and psoriatic arthritis patients. 2. Detect relation between TNFAIP3 and disease activity. Inclusion criteria: 1. Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984 (10). 2. Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010) (11). b. Exclusion criteria: Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.

What you commit to

• Study type: Interventional
• Planned participants: 110
• From 1 Apr 2026 to the primary completion date, 31 Dec 2028
• No sites listed in no country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov